# Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma

> **NCT00255723** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 98 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** carboplatin
- **DRUG:** etoposide
- **DRUG:** ifosfamide

## Key facts

- **NCT ID:** NCT00255723
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2016-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00255723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00255723, "Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00255723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*